Bronchitis - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Bronchitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Bronchitis - Pipeline Review, H2 2016', provides an overview of the Bronchitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bronchitis
- The report reviews pipeline therapeutics for Bronchitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Bronchitis therapeutics and enlists all their major and minor projects
- The report assesses Bronchitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Bronchitis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Bronchitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bronchitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Bronchitis Overview 7
Therapeutics Development 8
Pipeline Products for Bronchitis - Overview 8
Bronchitis - Therapeutics under Development by Companies 9
Bronchitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Bronchitis - Products under Development by Companies 13
Bronchitis - Companies Involved in Therapeutics Development 14
AstraZeneca Plc 14
DBV Technologies S.A. 15
F. Hoffmann-La Roche Ltd. 16
Hyundai Pharmaceutical Co., Ltd. 17
Invion Limited 18
Kyorin Pharmaceutical Co., Ltd. 19
Mucosis B.V. 20
Orbis Biosciences Inc 21
Recipharm AB 22
Bronchitis - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
alteplase - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
AZD-9668 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
erdosteine - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
HOB-051 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
KRPAM-1977X - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
nadolol - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
nitric oxide - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
prednisone - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
respiratory syncytial virus vaccine - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
SynGEM - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Bronchitis - Dormant Projects 50
Bronchitis - Discontinued Products 52
Bronchitis - Product Development Milestones 53
Featured News & Press Releases 53
Nov 10, 2015: Recipharm secures €25 million contract for Erdosteine API with Daewoong Pharmaceutical 53
Nov 10, 2015: Recipharm secures €25 million contract for Erdosteine API with Daewoong Pharmaceutical 53
Oct 07, 2015: EVP R&D Dr Mitchell Glass discusses with BRR media data from the Phase 2 clinical trial of INV102 (nadolol) in Smoking Cessation 54
Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets 54
Apr 21, 2015: Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings 55
Jan 23, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants 55
Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL 56
Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for Bronchitis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Bronchitis - Pipeline by AstraZeneca Plc, H2 2016 14
Bronchitis - Pipeline by DBV Technologies S.A., H2 2016 15
Bronchitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 16
Bronchitis - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 17
Bronchitis - Pipeline by Invion Limited, H2 2016 18
Bronchitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 19
Bronchitis - Pipeline by Mucosis B.V., H2 2016 20
Bronchitis - Pipeline by Orbis Biosciences Inc, H2 2016 21
Bronchitis - Pipeline by Recipharm AB, H2 2016 22
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Stage and Target, H2 2016 25
Number of Products by Stage and Mechanism of Action, H2 2016 27
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Bronchitis - Dormant Projects, H2 2016 50
Bronchitis - Dormant Projects (Contd..1), H2 2016 51
Bronchitis - Discontinued Products, H2 2016 52